562 related articles for article (PubMed ID: 18955864)
1. Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children.
Lykavieris P; Ducot B; Lachaux A; Dabadie A; Broué P; Sarles J; Bernard O; Jacquemin E
J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):623-9. PubMed ID: 18955864
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.
Jacquemin E; Hermans D; Myara A; Habes D; Debray D; Hadchouel M; Sokal EM; Bernard O
Hepatology; 1997 Mar; 25(3):519-23. PubMed ID: 9049190
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
[TBL] [Abstract][Full Text] [Related]
6. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease.
Puoti C; Magrini A; Filippi T; Annovazzi G; Pannullo A
Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):151-4. PubMed ID: 7712308
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants.
Al-Hathlol K; Al-Madani A; Al-Saif S; Abulaimoun B; Al-Tawil K; El-Demerdash A
Singapore Med J; 2006 Feb; 47(2):147-51. PubMed ID: 16435058
[TBL] [Abstract][Full Text] [Related]
8. Alpha-1-antitrypsin deficiency in children: liver disease is not reflected by low serum levels of alpha-1-antitrypsin - a study on 48 pediatric patients.
Lang T; Mühlbauer M; Strobelt M; Weidinger S; Hadorn HB
Eur J Med Res; 2005 Dec; 10(12):509-14. PubMed ID: 16356865
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice.
Treeprasertsuk S; Silachamroon U; Krudsood S; Huntrup A; Suwannakudt P; Vannaphan S; Wilairatana P
J Gastroenterol Hepatol; 2010 Feb; 25(2):362-8. PubMed ID: 19817958
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
[TBL] [Abstract][Full Text] [Related]
11. The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency.
Bernspång E; Carlson J; Piitulainen E
Scand J Gastroenterol; 2009; 44(11):1349-55. PubMed ID: 19891586
[TBL] [Abstract][Full Text] [Related]
12. [Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood--clinical and biochemical effects].
Kardorff R; Melter M; Rodeck B; Brodehl J
Klin Padiatr; 1996; 208(3):118-22. PubMed ID: 8676599
[TBL] [Abstract][Full Text] [Related]
13. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
14. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia.
Willot S; Uhlen S; Michaud L; Briand G; Bonnevalle M; Sfeir R; Gottrand F
Pediatrics; 2008 Dec; 122(6):e1236-41. PubMed ID: 19029197
[TBL] [Abstract][Full Text] [Related]
15. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.
Simko V; Michael S; Prego V
Am J Gastroenterol; 1994 Mar; 89(3):392-8. PubMed ID: 8122652
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy.
Rühl R; Seidensticker M; Peters N; Mohnike K; Bornschein J; Schütte K; Amthauer H; Malfertheiner P; Pech M; Ricke J
Dig Dis; 2009; 27(2):189-99. PubMed ID: 19546558
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience.
Zapata R; Sandoval L; Palma J; Hernández I; Ribalta J; Reyes H; Sedano M; Tohá D; Silva JJ
Liver Int; 2005 Jun; 25(3):548-54. PubMed ID: 15910492
[TBL] [Abstract][Full Text] [Related]
19. Variable degree of liver involvement in siblings with PiZZ alpha-1-antitrypsin deficiency-related liver disease.
Hinds R; Hadchouel A; Shanmugham NP; Al-Hussaini A; Chambers S; Cheeseman P; Mieli-Vergani G; Hadzić N
J Pediatr Gastroenterol Nutr; 2006 Jul; 43(1):136-8. PubMed ID: 16819392
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
